Cytokinetics, Incorporated
CYTKNASDAQHealthcare● Active
$69.95
$-1.53(-2.14%)
Market Cap$8.7B
P/E Ratio—
52W High$80.2
52W Low$31.52
Cytokinetics, Incorporated (CYTK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYTK · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $88.04M | $18.47M | $7.53M | $94.59M | $70.43M |
| Cost of Revenue | $10.13M | $339.41M | $330.12M | $240.81M | $159.94M |
| Gross Profit | $77.91M | ($320.93M) | ($322.59M) | ($146.22M) | ($89.51M) |
| Gross Margin %(computed) | 88.50% | — | — | -154.59% | -127.09% |
| Operating Expenses | |||||
| R&D Expenses | $405.90M | $339.41M | $330.12M | $240.81M | $159.94M |
| G&A Expenses | $284.27M | $215.31M | $173.61M | $177.98M | $96.80M |
| Total Operating Expenses | $690.17M | $215.31M | $173.61M | $177.98M | $96.80M |
| Operating Income | ($612.26M) | ($536.25M) | ($496.20M) | ($324.20M) | ($186.31M) |
| Operating Margin %(computed) | -695.44% | — | — | -342.75% | -264.54% |
| Interest Income | $48.42M | $51.53M | $27.63M | $11.34M | $0.33M |
| Interest Expense | $103.87M | $86.51M | $57.67M | $51.16M | $29.33M |
| Income Before Tax | ($784.96M) | ($589.53M) | ($526.24M) | ($388.95M) | ($215.31M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($784.96M) | ($589.53M) | ($526.24M) | ($388.95M) | ($215.31M) |
| Net Margin %(computed) | -891.60% | — | — | -411.21% | -305.72% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Wtd Avg Shares | 120.02M | 111.98M | 96.52M | 89.83M | 76.89M |
| EBITDA | ($775.27M) | ($493.48M) | ($456.68M) | ($329.40M) | ($176.34M) |
| EBITDA Margin %(computed) | -880.60% | — | — | -348.25% | -250.39% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Cytokinetics, Incorporated data
About Cytokinetics, Incorporated (CYTK) Income Statement
Cytokinetics, Incorporated (CYTK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CYTK reported revenue of $0.09B, gross profit of $0.08B (gross margin 88.50%), and net income of ($0.78B) — a net profit margin of -891.60%.
Frequently asked questions
CYTK · 4 questionsCytokinetics, Incorporated (CYTK) reported revenue of $0.09B for 2025, up 376.6% year-over-year.
CYTK revenueCYTK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08